Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 343

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 343
---
 take control of their health and enhance their quality of life. Our mission is to revolutionize healthcare by offering a suite of health evaluation services that fully integrate biological, clinical and lifestyle data (“multi -modaldata”) and AI. This innovative approach enhances the accuracy and effectiveness of precision medicine, leading to better health and more informed decisions for our customers. We were founded on and committed to the following principles: • Disrupting the healthcare industry: we are committed to transforming healthcare from impersonal and reactive to personalized and proactive. Through our innovative services, we seek to empower individuals to live healthier lives by providing secure, precise, and actionable biological insights. • Offering a suite of complementary genomic services: we are dedicated to providing a comprehensive suite of services that spans prevention, diagnostics and prognosis, integrating a wide range of multi -modaldata with AI. This approach enables precise, science -drivetools that support individuals with specific health conditions and those seeking to maintain or improve their overall health through preventive care strategies. • Building a strategic consortium: we are actively developing a consortium of laboratories and healthcare providers across the Americas to expand the availability of our prevention and clinical diagnostic products. We aim to launch the consortium following the establishment of our processing hub in Mexico. This hub may be wholly owned by us or developed through a hybrid partnership model, where manage key workflows such as NDA extraction and bioinformatics processing, while the partner laboratory handles sequencing. Establishing this hub will enable us to provide efficient processing services across the region and develop local markets for genomics services, as well as co -developingproducts based on identified local needs and opportunities. To facilitate the creation of the consortium, which we expect to develop within two years, we are engaging with various diagnostic laboratories that are part of the Asociación de Laboratorios de Diagnóstico de Latinoamérica, where one of our founders is also a founding member. Through this network, we are actively seeking partnerships to pilot our products and services, assess market demand, and identify the most promising SKUs to introduce in each market. As of the date of this registration statement on Form F -4, which includes this prospectus, four companies providing diagnostic services have indirectly invested in the Company through the Parent. These companies are Meyer Lab, Laboratorios LABIN, Amadita Laboratorio Clínico, and CIBIC, operating in Paraguay, Costa Rica, the Dominican Republic, and Argentina, respectively. • Integrating AI and genetic data: we obtain data from a diverse set of biological genomic sources